Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash & Current Investments: 2017-2019

Historic Cash & Current Investments for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $40.6 million.

  • Astria Therapeutics' Cash & Current Investments fell 6.07% to $40.6 million in Q3 2019 from the same period last year, while for Sep 2019 it was $176.0 million, marking a year-over-year increase of 39.02%. This contributed to the annual value of $37.6 million for FY2018, which is 129.52% up from last year.
  • Astria Therapeutics' Cash & Current Investments amounted to $40.6 million in Q3 2019, which was down 11.92% from $46.1 million recorded in Q2 2019.
  • In the past 5 years, Astria Therapeutics' Cash & Current Investments registered a high of $51.7 million during Q1 2019, and its lowest value of $16.4 million during Q4 2017.
  • In the last 3 years, Astria Therapeutics' Cash & Current Investments had a median value of $37.6 million in 2018 and averaged $35.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 46.44% in 2018, then skyrocketed by 203.37% in 2019.
  • Astria Therapeutics' Cash & Current Investments (Quarterly) stood at $16.4 million in 2017, then surged by 129.52% to $37.6 million in 2018, then dropped by 6.07% to $40.6 million in 2019.
  • Its Cash & Current Investments was $40.6 million in Q3 2019, compared to $46.1 million in Q2 2019 and $51.7 million in Q1 2019.